Cellin

Cellin is a South Korean biotechnology company focused on the development of next-generation regenerative medicines using stem cell and exosome technologies. Founded in 2015, the company leverages its proprietary platform for high-purity exosome isolation and standardized mesenchymal stem cell (MSC) cultivation to address unmet needs in inflammatory and degenerative diseases. Its lead therapeutic candidate, CI-001, is currently in clinical development for the treatment of atopic dermatitis, aiming to provide a long-term solution for chronic skin inflammation. The company's pipeline also includes programs for osteoarthritis and hair loss, utilizing the immunomodulatory and regenerative properties of MSC-derived exosomes. In addition to its clinical pursuits, Cellin applies its advanced cell research to the cosmeceutical industry, developing high-performance ingredients for skin rejuvenation and anti-aging.